Literature DB >> 20846097

Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia.

Ana P Gonzalez-Rodriguez1, Juan Contesti, Leticia Huergo-Zapico, Alejandro Lopez-Soto, Azahara Fernández-Guizán, Andrea Acebes-Huerta, Ana J Gonzalez-Huerta, Esther Gonzalez, Carmen Fernandez-Alvarez, Segundo Gonzalez.   

Abstract

The prognostic value of the number of T cells and NK cells at diagnosis in CLL was analyzed in a cohort of 256 patients with CLL diagnosed between 1997 and 2007. Patients with leukemia showed elevated NK cells and T cell populations and CD4/CD8 ratio was inverted in 39.7% cases. Prognostic significance of lymphocytes was analyzed as a ratio of relative number of T cells to the size of the malignant monoclonal B-cell pool (T/NK cells:Malignant monoclonal B-cells ratio). Patients showed higher relative number of CD4 (p = 0.03), CD8 (p = 0.02), and NK cells (p = 0.01) in early Rai stage of disease. The multivariate Cox analysis identified the relative number of CD8 (hazard ratio (HR) = 1.464; p = 0.006) and CD4 T cells (HR = 0.091; p < 0.01) as independent predictors for survival. Additionally, patients with relative CD8 count > 0.074 or CD4 count > 0.1 had higher 10-year overall survival than patients with CD8 count  ≤0.074 or CD4 count  ≤0.1 (p = 0.002). Higher CD8 count was associated with significantly higher median time of survival of patients (149.33 vs. 82.06 months). Finally, association of the good prognostic factor of leukemia cells (CD38⁻ with high relative CD8 count identified a group of patients with an indolent clinical course with an overall survival probability at 10 years of 95%.

Entities:  

Mesh:

Year:  2010        PMID: 20846097     DOI: 10.3109/10428194.2010.503820

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  30 in total

Review 1.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

2.  Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).

Authors:  Michael P Gustafson; Roshini S Abraham; Yi Lin; Wenting Wu; Dennis A Gastineau; Clive S Zent; Allan B Dietz
Journal:  Br J Haematol       Date:  2011-11-03       Impact factor: 6.998

3.  Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Authors:  Mónica Villa-Álvarez; Seila Lorenzo-Herrero; Ana P Gonzalez-Rodriguez; Alejandro López-Soto; Angel R Payer; Esther Gonzalez-Garcia; Leticia Huergo-Zapico; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

4.  NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Mitchell R Smith; R Katherine Alpaugh; Marion E Cole; Samuel Litwin; Michael M Millenson; Tahseen Al-Saleem; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

5.  Bringing natural killer cells to the clinic.

Authors:  Laura Chiossone; Eric Vivier
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

Review 6.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

7.  B-Cell Disorders and Curcumin.

Authors:  Terry Golombick; Terrence H Diamond; Arumugam Manoharan; Rajeev Ramakrishna
Journal:  Integr Cancer Ther       Date:  2015-12-16       Impact factor: 3.279

8.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

Review 9.  Targeting inflammatory pathways in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; Michael J Keating; Zeev Estrov
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-12       Impact factor: 6.312

Review 10.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.